Authors
Latest:
An Overview of Clinical Trials Investigating Immunotherapy Combos, Sequencing in MelanomaIgor Puzanov, MD, professor of oncology, Department of Medicine, Roswell Park Cancer Institute, discusses 2 clinical trials investigating immunotherapy combinations and sequencing in melanoma.
Latest:
Ilaria Muller on a Possible Common Antigen Between Thyroid and Breast CancersMuller says if this common antigen does exist, an immune therapy could hypothetically be developed to combat it and essentially combat both breast and thyroid cancer.
Latest:
Dr. Mayer Discusses Patient Selection for Emerging Therapies in Patients With ER+ mBCIngrid A. Mayer, MD, MSCI, discusses patient selection for emerging therapies in patients with ER-positive metastatic breast cancer (mBC).
Latest:
The Future of Immotherapy in Gynecologic CancersIra Winer, MD, PhD, assistant professor in the the Division of Gynecologic Oncology at Wayne State University, discusses the outlook on immunotherapy in the treatment landscape of gynecologic cancers.
Latest:
Multidrug Treatments Investigated in Smoldering Multiple MyelomaIrene Ghobrial, MD discusses multiple trials and their significance for treating patients with smoldering multiple myeloma and newly diagnosed multiple myeloma.
Latest:
Improving Outcomes, Value, and Data Collection in OncologyAn Abramson Cancer Center expert explains how departments can leverage informatics during the 10th Annual NANETS Symposium.
Latest:
Daratumumab as a Potential Treatment Option for Multiple MyelomaJacob Laubach, MD, MPP, from Dana-Farber Cancer Institute and an Instructor in Medicine at the Harvard Medical School, discusses daratumumab as a potential treatment option for patients with multiple myeloma.
Latest:
Locoregional Therapeutics: Using One's Own Tumor as a VaccineA locoregional approach to cancer vaccines, when combined with immunmodulatory antibody therapy, could generate a significant anti-tumor response.
Latest:
Selecting Patients for Treatment With Ibrutinib in CLLJacqueline C. Barrientos, MD, associate professor of the Karches Center for Oncology Research at the Feinstein Institute for Medical Research, discusses which types of patients with chronic lymphocytic leukemia are the best candidates for treatment with ibrutinib
Latest:
Novel Combination Strategies in CLLJacqueline C. Barrientos, MD, MS, discusses exciting novel combination strategies that are being presented at the 2019 ASH Annual meeting.
Latest:
Recent Advances in Mantle Cell LymphomaJacqueline D. Barrientos, MD, MS, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the most recent advances in mantle cell lymphoma, as well as the challenges investigators still face in the field.
Latest:
The Impact of Angelina Jolie's Story on Genetic ReferralsJacques Raphael, MD, clinical fellow, Sunnybrook Odette Cancer Centre, discusses a study looking at the impact of Angelina Jolie’s decision and announcement to undergo a preventive double mastectomy.
Latest:
Examining the Current Role of CAR T-Cell Therapy in Acute Myeloid LeukemiaJae H. Park, MD, discusses the current role and challenges in using CAR T-cell therapy in patients with relapsed or refractory acute myeloid leukemia. The 2 challenges now in this area are target selection and patient selection.
Latest:
CAR T-Cell Therapy Evolves in Leukemia Treatment LandscapeJae H. Park, MD, discusses the role of chimeric antigen receptor T-cell therapy in leukemias and how he sees this treatment evolving in the coming years.
Latest:
Despite Controversial 340B Payment Cuts, Study Suggests 85% of Hospitals Will See Payment IncreasesAs result of the Medicare Outpatient Prospective Payment System rule, 85% of 340B hospitals will see net payment increases in 2018, with rural hospitals reaping the largest benefits, according to an analysis conducted by Avalere Health that was commissioned by Community Oncology Alliance. This analysis compared 2017 Part B payments with 2018 payments and included 3814 hospitals.
Latest:
A Study of Secondary Cytoreductive Therapy in Platinum-Sensitive Ovarian CancerJalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité – Universitatsmedizin Berlin, discusses a randomized controlled phase II study to evaluate secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer.
Latest:
Key Takeaways for Neratinib Plus T-DM1 Combination in Breast CancerJame Abraham, MD, discusses the key takeaways from the phase Ib study of trastuzumab emtansine in combination with neratinib in patients with HER2-positive breast cancer.
Latest:
Cell Cycle Progression Score as a Predictor of Progression of ccRCCJames A. Brown, MD, Professor of Urology, Professor of Biomedical Engineering, University of Iowa Carver College of Medicine, discusses an analysis of cell cycle progression scores in patients with clear cell renal cell carcinoma (ccRCC) to evaluate its prognostic value.
Latest:
Unanswered Questions Regarding the Treatment of Pancreatic NETsJames C. Yao, MD, gives an overview of the questions that still remain regarding the treatment of pancreatic neuroendocrine tumors (NETs).
Latest:
Current TKI Therapy Practices and TKI Combinations in Lung CancerJames CH Yang, MD, PhD, Professor of Medicine, Deputy Director, Department of Medical Oncology, National Taiwan University Hospital, Director, Cancer Research, Center National Taiwan University College of Medicine, discusses current practices for administering TKI therapy and the potential for TKI combinations.
Latest:
Improving Clinical Trials in the Community SettingJames Hamrick, MD, senior medical director, Flatiron Health, discusses how clinical trials can be improved in the community setting during the ACCC 44th Annual Meeting & Cancer Center Business Summit.
Latest:
The Current State of the Treatment of Kidney CancerJames J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, provides an overview of the treatment of kidney cancer.
Latest:
Importance of Mismatched Repair Testing in CRCJames J. Lee, MD, PhD, assistant professor of medicine, Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, discusses the importance of mismatched repair testing in colorectal cancer (CRC).
Latest:
The Use of Endobronchial Ultrasound in Lung CancerJames Jett, MD, professor of Medicine Emeritus, National Jewish Health, discusses the use of endobronchial ultrasound (EBUS) in the diagnosis of lung cancer.
Latest:
Dr. Kearns Discusses PSA Genetic Correction in Prostate CancerJames Kearns, MD, discusses genetic correction of prostate-specific antigen (PSA) and how it can reduce the number of patients diagnosed with potentially insignificant prostate cancer
Latest:
Dr. James L. Gulley on Treatment Beyond the Second Line in Bladder CancerGulley says there is no standard procedure for the third line setting in bladder cancer, and that most oncologists would either turn to single-agent chemotherapy or to clinical trials.
Latest:
Expert Discusses Evolving Role of Genetic Testing in Prostate CancerJames L. Mohler, MD, discusses the evolving role of genetic testing in patients with prostate cancer following the updates to the National Cancer Care Network Guidelines, which now include guidance for better practice in terms of conducting genetic testing in this patient population.
Latest:
Differences in Screening for Lung CancerJames L. Mulshine, MD, professor, acting dean, Graduate College, Department of Internal Medicine, Rush Medical College, Rush University, discusses the worldwide differences in screening for lung cancer.
